170 related articles for article (PubMed ID: 36446254)
1. Targeting NaPi2b in ovarian cancer.
Banerjee S; Drapkin R; Richardson DL; Birrer M
Cancer Treat Rev; 2023 Jan; 112():102489. PubMed ID: 36446254
[TBL] [Abstract][Full Text] [Related]
2. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
Banerjee S; Oza AM; Birrer MJ; Hamilton EP; Hasan J; Leary A; Moore KN; Mackowiak-Matejczyk B; Pikiel J; Ray-Coquard I; Trask P; Lin K; Schuth E; Vaze A; Choi Y; Marsters JC; Maslyar DJ; Lemahieu V; Wang Y; Humke EW; Liu JF
Ann Oncol; 2018 Apr; 29(4):917-923. PubMed ID: 29401246
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers.
Lin K; Rubinfeld B; Zhang C; Firestein R; Harstad E; Roth L; Tsai SP; Schutten M; Xu K; Hristopoulos M; Polakis P
Clin Cancer Res; 2015 Nov; 21(22):5139-50. PubMed ID: 26156394
[TBL] [Abstract][Full Text] [Related]
4. Rebmab200, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted antibody therapy of cancer.
Lopes dos Santos M; Yeda FP; Tsuruta LR; Horta BB; Pimenta AA; Degaki TL; Soares IC; Tuma MC; Okamoto OK; Alves VA; Old LJ; Ritter G; Moro AM
PLoS One; 2013; 8(7):e70332. PubMed ID: 23936189
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of NaPi2b protein (MX35 antigen) expression and subcellular localization in human normal and cancer tissues.
Kiyamova R; Shyian M; Lyzogubov VV; Usenko VS; Gout T; Filonenko V
Exp Oncol; 2011 Sep; 33(3):157-61. PubMed ID: 21956469
[TBL] [Abstract][Full Text] [Related]
6. The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b.
Bodyak ND; Mosher R; Yurkovetskiy AV; Yin M; Bu C; Conlon PR; Demady DR; DeVit MJ; Gumerov DR; Gurijala VR; Lee W; McGillicuddy D; Park PU; Poling LL; Protopova M; Qin L; Stevenson CA; Ter-Ovanesyan E; Uttard A; Xiao D; Xu J; Xu L; Bergstrom DA; Lowinger TB
Mol Cancer Ther; 2021 May; 20(5):896-905. PubMed ID: 33722858
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b.
Levan K; Mehryar M; Mateoiu C; Albertsson P; Bäck T; Sundfeldt K
BMC Cancer; 2017 May; 17(1):303. PubMed ID: 28464843
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas.
Yin BW; Kiyamova R; Chua R; Caballero OL; Gout I; Gryshkova V; Bhaskaran N; Souchelnytskyi S; Hellman U; Filonenko V; Jungbluth AA; Odunsi K; Lloyd KO; Old LJ; Ritter G
Cancer Immun; 2008 Feb; 8():3. PubMed ID: 18251464
[TBL] [Abstract][Full Text] [Related]
9. The study of phosphate transporter NAPI2B expression in different histological types of epithelial ovarian cancer.
Gryshkova V; Goncharuk I; Gurtovyy V; Khozhayenko Y; Nespryadko S; Vorobjova L; Usenko V; Gout I; Filonenko V; Kiyamova R
Exp Oncol; 2009 Mar; 31(1):37-42. PubMed ID: 19300415
[TBL] [Abstract][Full Text] [Related]
10. In silico analysis and immunohistochemical characterization of NaPi2b protein expression in ovarian carcinoma with monoclonal antibody Mx35.
Soares IC; Simões K; de Souza JE; Okamoto OK; Wakamatsu A; Tuma M; Ritter G; Alves VA
Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):165-72. PubMed ID: 22553815
[TBL] [Abstract][Full Text] [Related]
11. Toward a Topology-Based Therapeutic Design of Membrane Proteins: Validation of NaPi2b Topology in Live Ovarian Cancer Cells.
Bulatova L; Savenkova D; Nurgalieva A; Reshetnikova D; Timonina A; Skripova V; Bogdanov M; Kiyamova R
Front Mol Biosci; 2022; 9():895911. PubMed ID: 35911971
[TBL] [Abstract][Full Text] [Related]
12. Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
Gerber DE; Infante JR; Gordon MS; Goldberg SB; Martín M; Felip E; Martinez Garcia M; Schiller JH; Spigel DR; Cordova J; Westcott V; Wang Y; Shames DS; Choi Y; Kahn R; Dere RC; Samineni D; Xu J; Lin K; Wood K; Royer-Joo S; Lemahieu V; Schuth E; Vaze A; Maslyar D; Humke EW; Burris HA
Clin Cancer Res; 2020 Jan; 26(2):364-372. PubMed ID: 31540980
[TBL] [Abstract][Full Text] [Related]
13. Sodium-dependent phosphate transporter NaPi2b as a potential predictive marker for targeted therapy of ovarian cancer.
Nurgalieva AK; Popov VE; Skripova VS; Bulatova LF; Savenkova DV; Vlasenkova RA; Safina SZ; Shakirova EZ; Filonenko VV; Bogdanov MV; Kiyamova RG
Biochem Biophys Rep; 2021 Dec; 28():101104. PubMed ID: 34504954
[TBL] [Abstract][Full Text] [Related]
14. Advances in antibody-drug conjugates for gynecologic malignancies.
Tymon-Rosario J; Gorman M; Richardson DL; Washington C; Santin AD
Curr Opin Obstet Gynecol; 2023 Feb; 35(1):6-14. PubMed ID: 36484278
[TBL] [Abstract][Full Text] [Related]
15. NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort.
Heynemann S; Yu H; Churilov L; Rivalland G; Asadi K; Mosher R; Hirsch F; Rivard C; Mitchell P
Clin Lung Cancer; 2022 Mar; 23(2):e90-e98. PubMed ID: 34953676
[TBL] [Abstract][Full Text] [Related]
16. Generation of monoclonal antibodies against tumor-associated antigen MX35/sodium-dependent phosphate transporter NaPi2b.
Gryshkova V; Lituiev D; Savinska L; Ovcharenko G; Gout I; Filonenko V; Kiyamova R
Hybridoma (Larchmt); 2011 Feb; 30(1):37-42. PubMed ID: 21466284
[TBL] [Abstract][Full Text] [Related]
17. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Vergote I; Ponte JF; Birrer MJ
Future Oncol; 2018 Jan; 14(2):123-136. PubMed ID: 29098867
[TBL] [Abstract][Full Text] [Related]
18. Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies.
Leung SOA; Konstantinopoulos PA
Expert Opin Investig Drugs; 2021 Jul; 30(7):695-707. PubMed ID: 34082614
[No Abstract] [Full Text] [Related]
19. Development of monoclonal antibodies specific for the human sodium-dependent phosphate co-transporter NaPi2b.
Kiyamova R; Gryshkova V; Ovcharenko G; Lituyev D; Malyuchik S; Usenko V; Khozhayenko Y; Gurtovyy V; Yin B; Ritter G; Old L; Filonenko V; Gout I
Hybridoma (Larchmt); 2008 Aug; 27(4):277-84. PubMed ID: 18724815
[TBL] [Abstract][Full Text] [Related]
20. Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.
Weekes CD; Lamberts LE; Borad MJ; Voortman J; McWilliams RR; Diamond JR; de Vries EG; Verheul HM; Lieu CH; Kim GP; Wang Y; Scales SJ; Samineni D; Brunstein F; Choi Y; Maslyar DJ; Colon-Otero G
Mol Cancer Ther; 2016 Mar; 15(3):439-47. PubMed ID: 26823490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
